IDH1 and acute myeloid leukemia: Adults age 18 - 75 with IDH1 R132-mutated AML, CMML, or MDS with normal organ and marrow function in CR post allo-HSCT. Patients with QTC > 500 or risk of QTC prolongation were excluded.